Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis.

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Rafael José Monteiro Da Silva Vieira

    Autor

  • João De Almeida Lopes Da Fonseca

    Autor

Participantes de fora da FMUP

  • Sousa-Pinto B
  • Bognanni A
  • Gil-Mata S
  • Ferreira-da-Silva R
  • Ferreira A
  • Cardoso-Fernandes A
  • Ferreira-Cardoso H
  • Marques-Cruz M
  • Duarte VH
  • Castro-Teles J
  • Campos-Lopes M
  • Teixeira-Ferreira A
  • Lourenço-Silva N
  • Chérrez-Ojeda I
  • Bedbrook A
  • Klimek L
  • Nuñez JJY
  • Zuberbier T
  • Schünemann HJ
  • Bousquet J
  • ARIA 2024 guideline panel

Unidades de investigação

Abstract

BACKGROUND: Intranasal antihistamines (INAH), corticosteroids (INCS), and their fixed combinations (INAH+INCS) are one of the cornerstones of the treatment of allergic rhinitis (AR). We performed a systematic review and network-meta-analysis comparing the efficacy and safety of INAH, INCS, and INAH+INCS in patients with AR. METHODS: We searched four electronic bibliographic databases and three clinical trial databases for randomised controlled trials assessing the use of INAH, INCS, and INAH+INCS in adults with seasonal or perennial AR. We performed a network meta-analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality-of-Life Questionnaire, development of adverse events, and withdrawals due to adverse events. Certainty of evidence was assessed using GRADE-NMA. RESULTS: We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine-fluticasone, and fluticasone furoate were the most frequently highest-ranked interventions for efficacy outcomes, being regularly associated with clinically meaningful larger improvements when compared to other active treatments. Considering drug classes, INAH+INCS were the highest-ranked interventions for all outcomes in which they were assessed, followed in most cases by INCS. In 105 out of 184 comparisons in seasonal AR, and 28 out of 97 comparisons in perennial AR, certainty of evidence was considered "high" or "moderate". CONCLUSION: Intranasal medications for AR display clinically relevant differences in their efficacy, but all show a good safety profile. To our knowledge, this is the first network meta-analysis comparing INAH, INCS, and INAH+INCS in AR, providing relevant evidence for guideline developers and practising physicians on the most efficacious treatments.

© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Dados da publicação

ISSN/ISSNe:
0105-4538, 1398-9995

ALLERGY  Wiley-Blackwell Publishing Ltd

Tipo:
Article
Páginas:
94-105
Link para outro recurso:
www.scopus.com

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • allergic rhinitis; antihistamines; corticosteroids; intranasal medications; network meta-analysis; systematic review

Proyectos asociados

Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021

Effect of a Mobile App on Improving Asthma Control in Adolescents and Adults With Persistent Asthma: A Pilot Randomized Multicentre, Superiority Clinical Trial (mINSPIRERS) - NCT05129527

Investigador Principal: João de Almeida Lopes da Fonseca

Ensaio Clínico Académico (mINSPIRERS) . 2021

Utilização em estudos observacionais do Registo de Asma Grave Portugal.

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Observacional Académico (RAG) . 2020

Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (CRC SHARP).

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Observacional (SHARP) . European Respiratory Society . 2021

Multidimensional phenotyping of severe asthma patients and its impact on disease control and therapeutic response - analysis from the Portuguese Severe Asthma Registry.

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Observacional (RAG-SPP-GSK) . SPPneumologia . 2022

BREATHE - An oBservational, pRimary data study to characterize severe AsThma pHenotypes and assEss disease burden across the EUCAN region.

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Observacional (RAG-AZ-BREATHE) . AstraZeneca . 2022

Efficiency in Spine Care ? Assessing outcomes and costs to inform healthcare improvement

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Académico . 2022

Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Académico . 2020

Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Académico . 2020

Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling

Investigador Principal: João de Almeida Lopes da Fonseca

Estudo Clínico Académico . 2020

Citar a publicação

Partilhar a publicação